相关实验视频

Updated: Jun 11, 2025

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

介质素-2 通过在肥胖小鼠中的下丘脑交感激活来改善胰岛素敏感性

Subin Moon¹, Yejin Park¹, Sooyeon Jang¹

¹Department of Biomedical Science, Hallym University, Chuncheon, 24252, Republic of Korea.

Journal of neuroinflammation

|October 4, 2024

概括

低剂量介素-2 (IL-2) 疗法通过增强调节性T细胞 (Tregs) 和调节神经免疫轴来增强胰岛素敏感性. 这种方法有可能用于治疗诸如肥胖和胰岛素抵抗等炎症性疾病.

科学领域:

免疫学免疫学免疫学
神经科学是一个神经科学.
代谢疾病代谢疾病

背景情况:

干白素-2 (IL-2) 不同调节T细胞子集:低剂量促进调节性T细胞 (Tregs),而高剂量激活细胞毒性细胞.
高剂量的IL-2正在用于癌症免疫疗法,但低剂量的IL-2在诸如肥胖和胰岛素抵抗等炎症性疾病中的潜力正在被研究.
肥胖和胰岛素抵抗的特点是低度慢性炎症.

研究的目的:

研究低剂量IL-2在治疗肥胖和胰岛素抵抗方面的治疗潜力.
阐明低剂量IL-2改善炎症条件下的胰岛素敏感性的机制.

主要方法:

在高脂肪饮食养的肥胖小鼠中,低剂量IL-2的全身和中心给药.
评估T细胞群 (Tregs,Th1细胞),炎症性细胞因子表达和胰岛素敏感性.
对交感神经系统的作用和在IL-2注射后的下丘脑微质症的研究.
淋巴腺白脂肪组织 (gWAT) 的交感变色,以评估其对IL-2效应的影响.

主要成果:

系统性低剂量IL-2增加了Treg细胞,减少了gWAT炎症,改善了胰岛素敏感性.
中央IL-2的管理通过交感神经系统激活增强了胰岛素敏感性.
中央IL-2调节的免疫细胞种群,减少了促炎性细胞因子 (IFNγ,IL-1β,IL-6,IL-8),并在gWAT中增加了Tregs和Tgfβ.
在中央IL-2中观察到下丘脑微质症和亲opiomelanocortin神经元激活.
交感性缺血逆转了IL-2诱导的胰岛素敏感性和免疫细胞概况的改善.

结论:

低剂量IL-2的使用改善了肥胖小鼠的胰岛素敏感性.
IL-2通过对CD4+T细胞的直接作用和间接通过涉及下丘脑微质症的神经免疫轴发挥其有益作用.
这些发现突出了使用低剂量IL-2治疗代谢和炎症疾病的新治疗策略.

关键词:

脂肪组织炎症脂肪组织炎症脑下垂体的微质细胞.胰岛素耐药性胰岛素耐药性是一种介质蛋白-2 介质蛋白-2 的作用.亲opiomelanocortin (POMC) 的神经元的神经元.同情神经系统的同情神经系统.

更多相关视频

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

相关概念视频

Insulin: The Receptor and Signaling Pathways

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...